Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Ocrevus 920 mg solution for injection

Active Ingredient:
ocrelizumab
Company:  
Roche Products Limited See contact details
ATC code: 
L04AG08
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

Ocrevus® Direct Healthcare Professional Communication for Healthcare Professionals based in Northern Ireland only

{healthcare_pro_orange} For Healthcare Professionals

Direct Healthcare Professional Communication on the significant update to premedication administration timing for patients on subcutaneous ocrelizumab in Northern Ireland (NI) to align with the UK Summary of Product Characteristics (SmPC) from 1st January 2025, as a result of the Windsor Framework Agreement.

This information is applicable to Healthcare Professionals based in Northern Ireland only.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Roche Products Limited
Company image
Address
Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
Telephone
+44 (0)1707 366 000
Fax
+44 (0)1707 338 297
Medical Information Direct Line
+44 (0)800 328 1629
Customer Care direct line
+44 (0)800 731 5711
Medical Information e-mail
[email protected]
Medical Information Fax
+44 (0)1707 384555
WWW
http://www.roche.co.uk